# US 2024/0402171 A1 · Corneal endothelial cell marker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0402171 A1
- Document ID: US20240402171A1
- Status: Published application
- Kind: A1
- Application number: 18/815,522
- Filed: 2024-08-26
- Published: 2024-12-05
- Earliest claimed: 2013-07-30
- Assignees: Kyoto Prefectural Public University Corporation; ActualEyes Inc.; Aurion Biotech, Inc.
- Applicants: Kyoto Prefectural Public University Corporation; Actualeyes Inc.; Aurion Biotech, Inc.
- Inventors: Noriko Koizumi; Naoki Okumura; Hiroatsu Hirano; Shigeru Kinoshita; Morio Ueno
- Web page: https://patentgrep.com/patent/US20240402171A1

## CPC

- G01N 33/56966: {Animal cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 27/02: Ophthalmic agents
- C12N 5/0621: {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062)}
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A method for determining the fibroblastic status of a corneal endothelial cell, comprising:
(a) contacting a sample comprising the corneal endothelial cell with one or more detection agents selected from:
(i) one or more detection agents selective for a cell-surface marker of corneal endothelial cells with a non-fibroblastic phenotype selected from the group consisting of CD166, HLA-A2, CD66a, CD66c, CD66d, CD66e, CD98, CD59, CD54, CD340, CD47, EGF-R, CD29, CD74, CD165, CD221, CD49a, SSEA-4, CD130, and CD49f, and
(ii) one or more detection agents selective for a cell-surface marker of corneal endothelial cells with a fibroblastic phenotype selected from the group consisting of CD26, CD9, CD49b, CD49e, CD13, CD99, CD105, CD63, CD58, CD201, CD56, CD44, CD55, CD71, CD73, CD91, HLA-DQ, CD164, CD49d, CD49c, CD90, MICA/B, CD46, CD140b, CD146, CD147, CD81, CD151, CD200, and CD10;
(b) detecting any recognition of the marker(s) by the detection agent(s); and
(c) determining the cell has a non-fibroblastic phenotype when a detected cell-surface marker of corneal endothelial cells with a non-fibroblastic phenotype is expressed at a higher level as compared to its expression level by a corneal endothelial cell with a fibroblastic phenotype, or
determining the cell has a fibroblastic phenotype when a detected cell-surface marker of corneal endothelial cells with a fibroblastic phenotype is expressed at a higher level as compared to its expression level by a corneal endothelial cell with a non-fibroblastic phenotype.

### Claim 27 (depends on 26)

The method of claim 26, wherein the method comprises contacting the sample with one or more detection agent(s) selective for a cell-surface marker selected from CD166, CD98, and CD340.

### Claim 28 (depends on 26)

The method of claim 26, wherein the method comprises contacting the sample with one or more detection agent(s) selective for a cell-surface marker selected from CD9, CD49e, CD44, and CD73.

### Claim 29 (depends on 26)

The method of claim 26, wherein the method comprises contacting the sample with a detection agent selective for cell-surface marker CD166.

### Claim 30 (depends on 26)

The method of claim 26, wherein the method comprises contacting the sample with a detection agent selective for cell-surface marker CD73.

### Claim 31 (depends on 26)

The method of claim 26, wherein the method comprises contacting the sample with a detection agent selective for cell-surface marker CD166 and a detection agent selective for cell-surface marker CD73.

### Claim 32

A method for differentiating between corneal endothelial cells with a non-fibroblastic phenotype and corneal endothelial cells with a fibroblastic phenotype in a sample comprising corneal endothelial cells with a non-fibroblastic phenotype and corneal endothelial cells with a fibroblastic phenotype, comprising at least one of:
detecting corneal endothelial cells with a non-fibroblastic phenotype in the sample by detecting at least one cell-surface marker of corneal endothelial cells with a non-fibroblastic phenotype selected from the group consisting of CD166, HLA-A2, CD66a, CD66c, CD66d, CD66e, CD98, CD59, CD54, CD340, CD47, EGF-R, CD29, CD74, CD165, CD221, CD49a, SSEA-4, CD130, and CD49f, wherein the detected cell-surface marker of corneal endothelial cells with a non-fibroblastic phenotype is expressed at a higher level as compared to the expression level of the same cell-surface marker by a corneal endothelial cell with a fibroblastic phenotype, and
detecting corneal endothelial cells with a fibroblastic phenotype in the sample by detecting at least one cell-surface marker of corneal endothelial cells with a fibroblastic phenotype selected from the group consisting of CD26, CD9, CD49b, CD49e, CD13, CD99, CD105, CD63, CD58, CD201, CD56, CD44, CD55, CD71, CD73, CD91, HLA-DQ, CD164, CD49d, CD49c, CD90, MICA/B, CD46, CD140b, CD146, CD147, CD81, CD151, CD200, and CD10, wherein the detected cell-surface marker of corneal endothelial cells with a fibroblastic phenotype is expressed at a higher level as compared to the expression level of the same cell-surface marker by a corneal endothelial cell with a non-fibroblastic phenotype.

### Claim 33 (depends on 32)

The method of claim 32, wherein the method comprises detecting one or more cell-surface markers selected from CD166, CD98, and CD340.

### Claim 34 (depends on 32)

The method of claim 32, wherein the method comprises detecting one or more cell-surface markers selected from CD9, CD49e, CD44, and CD73.

### Claim 35 (depends on 32)

The method of claim 32, wherein the method comprises detecting cell-surface marker CD166.

### Claim 36 (depends on 32)

The method of claim 32, wherein the method comprises detecting cell-surface marker CD73.

### Claim 37 (depends on 32)

The method of claim 32, wherein the method comprises detecting cell-surface marker CD166 and cell-surface marker CD73.

### Claim 38

A method of preparing a corneal endothelial cell sample with an elevated ratio of corneal endothelial cells with a non-fibroblastic phenotype to corneal endothelial cells with a fibroblastic phenotype, comprising:
in a corneal endothelial cell sample comprising cells with a non-fibroblastic phenotype and corneal endothelial cells with a fibroblastic phenotype, elevating the relative amount of corneal endothelial cells with a non-fibroblastic phenotype expressing one or more cell-surface markers of corneal endothelial cells with a non-fibroblastic phenotype selected from the group consisting of CD166, HLA-A2, CD66a, CD66c, CD66d, CD66e, CD98, CD59, CD54, CD340, CD47, EGF-R, CD29, CD74, CD165, CD221, CD49a, SSEA-4, CD130, and CD49f, at a higher level as compared to its expression level by a corneal endothelial cell with a fibroblastic phenotype, thereby obtaining a corneal endothelial cell sample with an elevated ratio of corneal endothelial cells with a non-fibroblastic phenotype to corneal endothelial cells with a fibroblastic phenotype.

### Claim 39 (depends on 38)

The method of claim 38, further comprising, administering the corneal endothelial cell sample with an elevated ratio of corneal endothelial cells with a non-fibroblastic phenotype to corneal endothelial cells with a fibroblastic phenotype to a subject in need of prevention or treatment of a corneal endothelial disease.

### Claim 40 (depends on 38)

The method of claim 38, wherein the method comprises elevating the relative amount of corneal endothelial cells expressing one or more cell-surface markers of corneal endothelial cells with a non-fibroblastic phenotype selected from CD166, CD98, and CD340 at a higher level as compared to its expression level by a corneal endothelial cell with a fibroblastic phenotype.

### Claim 41 (depends on 38)

The method of claim 38, wherein the method comprises elevating the relative amount of corneal endothelial cells expressing cell-surface marker CD166 at a higher level as compared to its expression level by a corneal endothelial cell with a fibroblastic phenotype.
